Roche to develop HCV (hepatitis C) genotyping assay:
This article was originally published in Clinica
Executive Summary
Roche Diagnostics has licensed hepatitis C (HCV) genotyping technology from Belgian pharmaceutical firm Innogenetics to develop a test that will help doctors tailor therapy better. The assay will identify which of the six different types of HCV a patient is infected with. Certain types of HVC require more aggressing treatment. Under the worldwide non-exclusive license, Roche will pay Gent-based Innogenetics an up-front license fee together with royalty payments on eventual product sales.